Category Archives: Immunology

Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR … – Yahoo Finance

STRASBOURG, France--(BUSINESS WIRE)--

Regulatory News:

Transgene (TNG.PA), a biotechnology company focused on designing and developing viral-based immune-targeted therapies for the treatment of cancers and infectious diseases, announces today that it will present a poster with new and encouraging preclinical data of a next generation armed engineered oncolytic virus at the American Association for Cancer Research annual meeting in Washington, DC.

This immunological data further support the development of armed oncolytic viruses that have the capacity to modulate the tumor micro-environment and improve T-cell infiltration in the tumor.

Key highlights:

The poster entitled Local and abscopal effects in oncolytic virotherapy are boosted by immune checkpoint blockade, immunogenic chemotherapy, or IFNAR blockade will be presented on Tuesday, April 4th, from 1:00 to 5:00pm EST in the section25. The abstract is available on the AACR website.

The poster presents preclinical results of a modified vaccinia virus expressing the Fcu1 gene (VVWR-TK-RR--Fcu1), which is able to transform the non-cytotoxic pro-drug, flucytosine (5-FC), into 5-FU, a widely used cancer chemotherapy. Results show that this next generation armed oncolytic virus is able to induce an immunogenic cell death and thus to generate a systemic immune response in immuno-competent mouse models.

These preclinical data further strengthen the preclinical data package of Transgenes most advanced next generation oncolytic virus, TG6002. TG6002 is due to enter the clinic in H12017 in patients with recurrent glioblastoma.

About Transgene Transgene S.A. (TNG.PA), part of Institut Mrieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Companystwo lead clinical-stage programs are: TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The Company has several other programs in clinical and preclinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at http://www.transgene.fr.

Follow us on Twitter: @TransgeneSA

Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Companys activities, perspectives, financial situation, results, regulatory authorities agreement with development phases, and development. The Companys ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Companys actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (Facteurs de Risque) section of the Document de Rfrence, available on the AMF website (http://www.amf-france.org) or on Transgenes website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005720/en/

More here:
Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR ... - Yahoo Finance

Following industry trend, Merck offloads mid-stage immunology candidate – The Pharma Letter (registration)

Merck KGaA and London-based Avillion have signed an agreement to collaborate on the development of the

To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever.

Avillion LLPBiotechnologyDealsGermanyImmunologicalsLicensingMerck KGaAUK

Access The Pharma Letter's latest news free for 7 days

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Click here to take a free trial

Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year

Click here to subscribe

Here is the original post:
Following industry trend, Merck offloads mid-stage immunology candidate - The Pharma Letter (registration)

Immune Deficiency Foundation Continues Partnership with Clinical Immunology Society to Promote – PR Newswire (press release)

As organizations that work closely with the PI community, IDF and CIS want to educate the public about PI during Awareness Month and World PI Week. Although some types present at birth or in early childhood, the disorders can affect anyone, regardless of age or gender. They are caused by hereditary or genetic defects and are not contagious.

Theme of World PI Week Focuses on Access to Ig Therapy Leading up to and throughout World PI Week, IDF and CIS will lead the PI community in raising awareness and improving access to lifesaving immunoglobulin replacement (Ig) therapy for people with these rare, chronic conditions. Ig replacement therapy, which is derived from human plasma, provides antibodies to protect against a broad range of infections, and it is life sustaining and lifelong for many with PI. Such treatments exist for people with PI, but access to them can vary significantly across continents and countries of a same region. The World PI Week aims to help drive change and equal access to quality treatment for all patients.

CIS Annual Meeting Kicked off Awareness Month During the CIS Annual Meeting, held March 23-26, 2017 in Seattle, members of CIS presented new research findings and discussed treatments for PI with more than 600 meeting attendees. Serving as a kick-off for Awareness Month and World PI Week, IDF staff members also participated and shared the Foundation's resources for the PI community. The organizations will also mail IDF educational materials to all CIS members.

"The Clinical Immunology Society promotes excellence in the care of patients with immunologic/inflammatory disorders, including primary immunodeficiency diseases. It is essential that patients receive proper treatment under the care of a specialist," Roshini Sarah Abraham, PhD, CIS President. "We are proud to partner with IDF during Awareness Month and World PI Week to help increase awareness of these complex diseases and to ensure access to lifesaving treatments."

With early diagnosis and proper medical care, many people with PI can live long, healthy lives. For more information, visit http://www.primaryimmune.org or call 800-296-4433.

World PI Week: April 22-29 IDF and CIS are joining organizations across the globe to promote awareness of primary immunodeficiency diseases during World PI Week, April 22-29. IDF participates in international initiatives with the objective to Test, Diagnose and Treat! For more information about World PI Week, visit http://www.worldpiweek.org.

About the Immune Deficiency Foundation The Immune Deficiency Foundation (IDF), founded in 1980, is the national non-profit patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases (PI) through advocacy, education and research. IDF provides accurate and timely information for individuals and families living with PI and offers valuable resources. To learn more about IDF, visit http://www.primaryimmune.org.

About the Clinical Immunology Society The Clinical Immunology Society (CIS), established in 1986, is devoted to fostering developments in the science and practice of clinical immunology. CIS works to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic/inflammatory disorders. To learn more about CIS, visit http://www.clinimmsoc.org.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immune-deficiency-foundation-continues-partnership-with-clinical-immunology-society-to-promote-national-primary-immunodeficiency-awareness-month-and-world-pi-week-in-april-300432237.html

SOURCE Immune Deficiency Foundation

http://www.primaryimmune.org

Follow this link:
Immune Deficiency Foundation Continues Partnership with Clinical Immunology Society to Promote - PR Newswire (press release)

New England Allergy, Asthma & Immunology PC Hosts 23-Nation Delegation of Top Healthcare Officials – Yahoo Finance

NORTH ANDOVER, Mass., March 28, 2017 /PRNewswire/ --New England Allergy, Asthma & Immunology P.C. is New England's largest and most prominent private practice specializing in allergy, asthma, and immunology - http://www.newenglandallergy.com. In partnership with local and governmental organizations, hosted an international delegation of health experts and government officials as part of a Global Health Initiative to promote international cooperation on the common challenges facing the global community in the prevention, treatment, and management of multi-disciplinary health problems affecting general populations, including allergy, asthma, immune illnesses, infectious diseases, cancer, stroke, heart disease and diabetes.

The event was held at the Atkinson Resort & Country Club in Atkinson, NH.

The delegation was comprised of Secretaries and Assistant Secretaries of Health, Program Directors, CEOs, Program Officers, Medical Officers, and many professors and researchers from:

"We are honored and equally humbled to host a delegation of this caliber at our home institution," said Dr. Thomas F. Johnson, Founder, Owner, and Chief Medical Officer of New England Allergy. "This speaks volumes to our commitment to promote the best health standards and to our full endorsement of a borderless world where every nation serves as a building block in global health initiatives to help prevent and combat disease."

"New England Allergy, Asthma & Immunology is pioneering a global system of collaboration across geographies and across medical disciplines to facilitate knowledge transfer, preventative screening, treatment, and efficient healthcare delivery systems," said George Kassas, CEO of Bireme Systems LLC, the Business Managing firm of New England Allergy. "This distinguished delegation's visit reaffirms New England Allergy's mission to welcome patients from all over the world to receive the very best care from many different medical subspecialties centered from our growing, premier facility."

New England Allergy, Asthma & Immunology P.C. http://www.newenglandallergy.com is located in North Andover, M.A. with offices in Lowell, M.A., Newburyport, M.A., Salem, N.H., Hampstead, N.H., and Hooksett, N.H. To learn more about the services offered by the practice, please visit http://www.newenglandallergy.com.

Media Contact:George Kassas+1508-523-4432George.kassas@newenglandallergy.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-england-allergy-asthma--immunology-pc-hosts-23-nation-delegation-of-top-healthcare-officials-300429806.html

View original post here:
New England Allergy, Asthma & Immunology PC Hosts 23-Nation Delegation of Top Healthcare Officials - Yahoo Finance

Two Postdoctoral Fellows Researching Immunology and Cancer … – SelectScience

ACEA Biosciences, a privately owned biotechnology company that develops cutting edge instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy scientists who will be presenting research using ACEA Biosciences technology at scientific conferences. Today the company announced that its new round of awards are being given to two postdoctoral fellows studying pathogen capture by neutrophils, and the impact of epigenetics on chemotherapy efficacy.

Dr. Calum Robb (pictured left), a postdoctoral fellow in the laboratory of Dr. Adriano Rossi at the University of Edinburgh Medical School, was selected for his poster entitled Flow cytometric assessment, quantification and regulation of human neutrophil extracellular traps which he will present at the CYTO 2017 Conference being held June 10-14 in Boston, MA. Beyond their well characterized role as phagocytes, granulocytic neutrophils are also able to ensnare and neutralize pathogens using a secreted extracellular fibril matrix consisting of DNA, histones, and a variety of anti-bacterial proteins. Though the employment of these neutrophil extracellular traps (NETs) is thought to be an evolutionarily ancient defense strategy, the mechanisms regulating this process are not yet fully understood. With the goal of elucidating these mechanisms, Robb developed a NovoCyte flow cytometer-based assay that enabled him to track changes in NET formation when key proteins or pathways were pharmacologically modulated. Using this approach, Robb probed the roles of superoxide anion, intracellular calcium pools, and the phospholipase C pathway in NET formation. The efficiency and versatility of Robbs assay are expected to accelerate the rate of progress in this relatively new field.

Dr. Rentian Wu(pictured right), a postdoc in the lab of Dr. Robert Diasio at the Mayo Clinic, was selected for his poster entitled Trimethylation and acetylation of histone H3K27 modulates 5-fluorouracil response by regulating DPYD expression which he will present at the 2017 American Association for Cancer Research meeting taking place April 1-5 in Washington D.C. Though it is one of the most widely used chemotherapy drugs, the antimetabolite 5-fluorouracil (5-FU) displays substantial variability in its efficacy and toxicity among patients. This variability is due, at least in part, to differences in the activity of DPD, the enzyme which initiates the catabolic degradation of 5-FU to inactive metabolites. Though mutations in the DPD gene can affect 5-FU metabolism, these variants are rare and cannot by themselves explain the variation in DPD activity that is observed among patients. In search for the cause of variable DPD activity, Wu used the xCELLigence Real-Time Cell Analyzer in combination with both chemical inhibitors and genetic approaches to demonstrate that the DPD gene is epigenetically regulated by histone modification at promoter and enhancer regions. This new layer of information has the potential to help clinicians predict more accurately how a patient will respond to 5-FU treatment.

To learn more about ACEAs Travel Award, see profiles of past winners, or download the application form for future funding cycles, click here.

More here:
Two Postdoctoral Fellows Researching Immunology and Cancer ... - SelectScience

New England Allergy, Asthma & Immunology PC Hosts 23-Nation Delegation of Top Healthcare Officials – PR Newswire (press release)

The delegation was comprised of Secretaries and Assistant Secretaries of Health, Program Directors, CEOs, Program Officers, Medical Officers, and many professors and researchers from:

"We are honored and equally humbled to host a delegation of this caliber at our home institution," said Dr. Thomas F. Johnson, Founder, Owner, and Chief Medical Officer of New England Allergy. "This speaks volumes to our commitment to promote the best health standards and to our full endorsement of a borderless world where every nation serves as a building block in global health initiatives to help prevent and combat disease."

"New England Allergy, Asthma & Immunology is pioneering a global system of collaboration across geographies and across medical disciplines to facilitate knowledge transfer, preventative screening, treatment, and efficient healthcare delivery systems," said George Kassas, CEO of Bireme Systems LLC, the Business Managing firm of New England Allergy. "This distinguished delegation's visit reaffirms New England Allergy's mission to welcome patients from all over the world to receive the very best care from many different medical subspecialties centered from our growing, premier facility."

New England Allergy, Asthma & Immunology P.C. http://www.newenglandallergy.com is located in North Andover, M.A. with offices in Lowell, M.A., Newburyport, M.A., Salem, N.H., Hampstead, N.H., and Hooksett, N.H. To learn more about the services offered by the practice, please visit http://www.newenglandallergy.com.

Media Contact:George Kassas+1508-523-4432George.kassas@newenglandallergy.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-england-allergy-asthma--immunology-pc-hosts-23-nation-delegation-of-top-healthcare-officials-300429806.html

SOURCE New England Allergy, Asthma & Immunology P.C.

Home

Original post:
New England Allergy, Asthma & Immunology PC Hosts 23-Nation Delegation of Top Healthcare Officials - PR Newswire (press release)

IMMUNOLOGY 2017 May 12 16, 2017 | Washington, D.C.

Development of Inexpensive Multiplex Immunoassays: Assessment of Food Allergens in Plasma

1:45 AM 2:30 PM EXHIBITOR WORKSHOP ROOM 2 SCIENION US, Inc.

Presenter:

Attack by foreign substances, such as allergens, triggers a cascade of events, in which IgE is a first responder. An allergic reaction to certain foods, e.g., shellfish or peanuts, can elicit a response within minutes of ingestion. There are also more subtle responses, such as IgG, which remains in the bloodstream for an extended period, and is monitored to assess this delayed response. Th2 cytokines are involved in the humoral response, leading to the production ofIgE antibodies. Other cytokines, such as IL-25, are also involved in the induction of Th2 responses. In this study, a microplate-based microarray of allergenic proteins from food sources was constructed together with antibodies to measure inflammatory cytokines. Plasma from patients with known food allergy was assessed for specific IgG subclasses, specific IgE, and Th2 cytokine levels. Quantitative multiplex immunoassays were performed, and resulted in bright and colorful spots. The plates were analyzed using a novel colorimetric microplate imaging reader (sciREADER CL2, Scienion).

The rest is here:
IMMUNOLOGY 2017 May 12 16, 2017 | Washington, D.C.

Immunology Conference | Immunology Meeting 2017 | Malaysia | Asia

Scientific Sessions

Session Tracks

Conference Series invites all the participants from all over the world to attend"9th Annual Meeting on Immunology and Immunologist, July 03-04, 2017 Kuala Lumpur,Malaysiaincludesprompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

TheImmunology conferencesdeals with the major branches like Classical immunology, Clinical immunology, Osteoimmunology,Medicine immunology, Tissue-based immunology. It will broadly classify the cells of immune system, autoimmune diseases, antigen-antibody reactions, T cell development, B cell development, cytokines etc. Immunology has applications in numerous disciplines of medicine, particularly in the fields of organ transplantation,oncology, virology, bacteriology, parasitology, psychiatry, and dermatology. Immunologists employed by universities work in virtually every life science department or division conducting research to increase our understanding of the immune system.

Track:1Cellular Immunology

The study of the molecular and cellular components that comprise the immune system, including their function and interaction, is the central science ofimmunology. The immune system has been divided into a more primitive innate immune system and, in vertebrates, an acquired oradaptive immune system

The field concerning the interactions among cells and molecules of the immunesystem,and how such interactions contribute to the recognition and elimination of pathogens. Humans possess a range of non-specific mechanical and biochemical defences against routinely encountered bacteria, parasites, viruses, and fungi. The skin, for example, is an effective physical barrier to infection. Basic chemical defences are also present in blood, saliva, and tears, and on mucous membranes. True protection stems from the host's ability to mount responses targeted to specific organisms, and to retain a form of memory that results in a rapid, efficient response to a given organism upon a repeat encounter. This more formal sense of immunity, termed adaptive immunity, depends upon the coordinated activities of cells and molecules of the immune system.

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 2Inflammatory/Autoimmune Diseases

Autoimmune diseasescan affect almost any part of the body, including the heart, brain, nerves, muscles, skin, eyes, joints, lungs, kidneys, glands, the digestive tract, and blood vessels.

The classic sign of an autoimmune disease is inflammation, which can cause redness, heat, pain, and swelling. How an autoimmune disease affects you depends on what part of the body is targeted. If the disease affects the joints, as inrheumatoid arthritis, you might have joint pain, stiffness, and loss of function. If it affects the thyroid, as in Graves disease and thyroiditis, it might cause tiredness, weight gain, and muscle aches. If it attacks the skin, as it does in scleroderma/systemic sclerosis, vitiligo, andsystemic lupus erythematosus(SLE), it can cause rashes, blisters, and colour changes. Many autoimmune diseases dont restrict themselves to one part of the body. For example, SLE can affect the skin, joints, kidneys, heart, nerves, blood vessels, and more. Type 1 diabetes can affect your glands, eyes, kidneys, muscles, and more.

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 3T-Cells and B-Cells

T cell: A type of white blood cell that is of key importance to the immune system and is at the core of adaptive immunity, the system that tailors the body's immune response to specific pathogens. The T cells are like soldiers who search out and destroy the targeted invaders. Immature T cells (termed T-stem cells) migrate to the thymus gland in the neck, where they mature and differentiate into various types of mature T cells and become active in the immune system in response to a hormone called thymosin and other factors. T-cells that are potentially activated against the body's own tissues are normally killed or changed ("down-regulated") during this maturational process.There are several different types of mature T cells. Not all of their functions are known. T cells can produce substances called cytokines such as the interleukins which further stimulate the immune response. T-cell activation is measured as a way to assess the health of patients withHIV/AIDSand less frequently in other disorders. T cell are also known as T lymphocytes. The "T" stands for "thymus" -- the organ in which these cells mature. As opposed to B cells which mature in the bone marrow.B cells, also known asBlymphocytes, are a type of white bloodcellof the lymphocyte subtype. They function in thehumoral immunitycomponent of the adaptive immune system by secreting antibodies. Many B cells mature into what are called plasma cells that produce antibodies (proteins) necessary to fight off infections while other B cells mature into memory B cells. All of the plasma cells descended from a single B cell produce the same antibody which is directed against the antigen that stimulated it to mature. The same principle holds with memory B cells. Thus, all of the plasma cells and memory cells "remember" the stimulus that led to their formation. The maturation of B cells takes place in birds in an organ called the bursa of Fabricus. B cells in mammals mature largely in the bone marrow. The B cell, or B lymphocyte, is thus an immunologically important cell. It is not thymus-dependent, has a short lifespan, and is responsible for the production ofimmunoglobulins.It expresses immunoglobulins on its surface.

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology Germany

.http://annualmeeting.conferenceseries.com/immunologist/

Track: 4Cancer and Tumor Immunobiology

The tumour is an important aspect of cancer biology that contributes to tumour initiation, tumour progression and responses to therapy. Cells and molecules of the immune system are a fundamental component of the tumour microenvironment. Importantly,therapeutic strategies for cancer treatmentcan harness the immune system to specifically target tumour cells and this is particularly appealing owing to the possibility of inducing tumour-specific immunological memory, which might cause long-lasting regression and prevent relapse in cancer patients.The composition and characteristics of the tumour microenvironment vary widely and are important in determining the anti-tumour immune response.Immunotherapyis a new class ofcancer treatmentthat works to harness the innate powers of the immune system to fight cancer. Because of the immune system's unique properties, these therapies may hold greater potential than current treatment approaches to fight cancer more powerfully, to offer longer-term protection against the disease, to come with fewer side effects, and to benefit more patients with more cancer

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 5 Vaccines

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. There are two basictypes of vaccines: live attenuated and inactivated. The characteristics of live and inactivatedvaccinesare different, and these characteristics determine how thevaccineis used. Liveattenuatedvaccinesare produced by modifying a disease-producing (wild) virus or bacteria in a laboratory.

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 6Immunotherapy

Immunotherapy,also called biologic therapy, is a type of cancer treatment designed to boost the body's natural defences to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. Immunotherapy is treatment that uses certain parts of a persons immune system to fight diseases such as cancer. This can be done in a couple of ways:1)Stimulating your own immune system to work harder or smarter to attack cancer cells2)Giving you immune system components, such as man-made immune system proteins. Some types of immunotherapy are also sometimes called biologic therapy or biotherapy.

In the last few decadesimmunotherapyhas become an important part of treating some types of cancer. Newer types of immune treatments are now being studied, and theyll impact how we treat cancer in the future. Immunotherapy includes treatments that work in different ways. Some boost the bodys immune system in a very general way. Others help train the immune system to attack cancer cells specifically. Immunotherapy works better for some types of cancer than for others. Its used by itself for some of these cancers, but for others it seems to work better when used with other types of treatment.

Many different types of immunotherapy are used to treat cancer. They include:Monoclonal antibodies,Adoptive cell transfer,Cytokines, Treatment Vaccines, BCG,

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 7Neuro Immunology

Neuroimmunology, a branch of immunologythat deals especially with the inter relationships of the nervous system and immune responses andautoimmune disorders. It deals with particularly fundamental and appliedneurobiology,meetings onneurology,neuropathology, neurochemistry,neurovirology, neuroendocrinology, neuromuscular research,neuropharmacologyand psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays).

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 8Infectious Diseases and Immune System

Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi; the diseases can be spread, directly or indirectly, from one person to another.Zoonotic diseasesare infectious diseases of animals that can cause disease when transmitted to humans. Some infectious diseases can be passed from person to person. Some are transmitted by bites from insects or animals. And others are acquired by ingesting contaminated food or water or being exposed to organisms in the environment. Signs and symptoms vary depending on the organism causing the infection, but often include fever and fatigue. Mild complaints may respond to rest and home remedies, while some life-threatening infections may require hospitalization.

Many infectious diseases, such as measles andchickenpox, can be prevented by vaccines. Frequent and thorough hand-washing also helps protect you from infectious diseases

There are four main kinds of germs:

Bacteria - one-celled germs that multiply quickly and may release chemicals which can make you sick

Viruses - capsules that contain genetic material, and use your own cells to multiply

Fungi - primitive plants, like mushrooms or mildew

Protozoa - one-celled animals that use other living things for food and a place to live

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 9Reproductive Immunology,

Reproductive immunologyrefers to a field of medicine that studies interactions (or the absence of them) between the immune system and components related to thereproductivesystem, such as maternal immune tolerance towards the fetus, orimmunologicalinteractions across the blood-testis barrier. The immune system refers to all parts of the body that work to defend it against harmful enemies. In people with immunological fertility problems their body identifies part of reproductive function as an enemy and sendsNatural Killer (NK) cellsto attack. A healthy immune response would only identify an enemy correctly and attack only foreign invaders such as a virus, parasite, bacteria, ect.

The concept of reproductive immunology is not widely accepted by all physicians.Those patients who have had repeated miscarriages and multiple failed IVF's find themselves exploring it's possibilities as the reason. With an increased amount of success among treating any potential immunological factors, the idea of reproductive immunology can no longer be overlooked.The failure to conceive is often due to immunologic problems that can lead to very early rejection of the embryo, often before the pregnancy can be detected by even the most sensitive tests. Women can often produce perfectly healthy embryos that are lost through repeated "mini miscarriages." This most commonly occurs in women who have conditions such asendometriosis, an under-active thyroid gland or in cases of so called "unexplained infertility." It has been estimated that an immune factor may be involved in up to 20% of couples with otherwiseunexplained infertility. These are all conditions where abnormalities of the womans immune system may play an important role.

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track:10Auto Immunity,

Autoimmunityis the system ofimmuneresponses of an organism against its own cells and tissues. Any disease that results from such an aberrantimmuneresponse is termed an autoimmune disease.

Autoimmunity is present to some extent in everyone and is usually harmless. However, autoimmunity can cause a broad range of human illnesses, known collectively as autoimmune diseases. Autoimmune diseases occur when there is progression from benign autoimmunity to pathogenicautoimmunity. This progression is determined by genetic influences as well as environmental triggers. Autoimmunity is evidenced by the presence of autoantibodies (antibodies directed against the person who produced them) and T cells that are reactive with host antigens.

Autoimmune disorders

An autoimmune disorder occurs whenthe bodys immune systemattacks and destroys healthy body tissue by mistake. There are more than 80 types of autoimmune disorders.

Causes

The white blood cells in the bodys immune system help protect against harmful substances. Examples include bacteria, viruses,toxins,cancercells, and blood and tissue from outside the body. These substances contain antigens. The immune system producesantibodiesagainst these antigens that enable it to destroy these harmful substances. When you have an autoimmune disorder, your immune system does not distinguish between healthy tissue and antigens. As a result, the body sets off a reaction that destroys normal tissues. The exact cause of autoimmune disorders is unknown. One theory is that some microorganisms (such as bacteria or viruses) or drugs may trigger changes that confuse the immune system. This may happen more often in people who have genes that make them more prone toautoimmune disorders.

An autoimmune disorder may result in:

The destruction of body tissue

Abnormal growth of an organ

Changes in organ function

A person may have more than one autoimmune disorder at the same time. Common autoimmune disorders include:

Addison's disease

Celiac disease - sprue(gluten-sensitive enteropathy)

Dermatomyositis

Graves' disease

Hashimoto's thyroiditis

Multiple sclerosis

Myasthenia gravis

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 11Costimmulatory pathways in multiple sclerosis

Costimulatory moleculescan be categorized based either on their functional attributes or on their structure. The costimulatory molecules discussed in this review will be divided into (1)positive costimulatory pathways:promoting T cell activation, survival and/or differentiation; (2)negative costimulatory pathways:antagonizing TCR signalling and suppressing T cell activation; (3) as third group we will discuss themembers of the TIM family, a rather new family of cell surface molecules involved in the regulation of T cell differentiation and Treg function.Costimulatory pathways have a critical role in the regulation of alloreactivity. A complex network of positive and negative pathways regulates T cell responses. Blocking costimulation improves allograft survival in rodents and non-human primates. The costimulation blocker belatacept is being developed asimmunosuppressivedruginrenal transplantation.

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 12Autoimmunity and Therapathies

Autoimmunityis the system ofimmuneresponsesof an organism against its own cells and tissues. Any disease that results from such an aberrantimmuneresponse is termed an autoimmune disease.

Autoimmunity is present to some extent in everyone and is usually harmless. However, autoimmunity can cause a broad range of human illnesses, known collectively as autoimmune diseases.Autoimmune diseasesoccur when there is progression from benign autoimmunity to pathogenic autoimmunity. This progression is determined by genetic influences as well as environmental triggers. Autoimmunity is evidenced by the presence of autoantibodies (antibodies directed against the person who produced them) and T cells that are reactive with host antigens.

Current treatments for allergic and autoimmune disease treat disease symptoms or depend on non-specific immune suppression. Treatment would be improved greatly by targeting the fundamental cause of the disease, that is the loss of tolerance to an otherwise innocuous antigen in allergy or self-antigen in autoimmune disease (AID). Much has been learned about the mechanisms of peripheral tolerance in recent years. We now appreciate that antigen presenting cells (APC) may be either immunogenic or tolerogenic, depending on their location, environmental cues and activation state

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track: 13DiagnosticImmunology

Diagnostic Immunology. Immunoassays are laboratory techniques based on the detection of antibody production in response to foreign antigens. Antibodies, part of the humoral immune response, are involved in pathogen detection and neutralization.

Diagnostic immunology has considerably advanced due to the development of automated methods.New technology takes into account saving samples, reagents, and reducing cost.The future of diagnosticimmunologyfaces challenges in the vaccination field for protection against HIV and asanti-cancer therapy. Modern immunology relies heavily on the use of antibodies as highly specific laboratory reagents. The diagnosis of infectious diseases, the successful outcome of transfusions and transplantations, and the availability of biochemical and hematologic assays with extraordinary specificity and sensitivity capabilities all attest to the value of antibody detection.Immunologic methods are used in the treatment and prevention ofinfectious diseasesand in the large number of immune-mediated diseases. Advances in diagnostic immunology are largely driven by instrumentation, automation, and the implementation of less complex and more standardized procedures.

Examples of such processes are as follows:

miniaturization (use of microtiter plates to save samples and reagents),

amplified immunoassays (chemiluminesent ELISA),

flow cytometry with monoclonal antibodies,

Immunoglobulins,

Molecular methods (polymerase chain reactions).

These methods have facilitated the performance of tests and have greatly expanded the information that can be developed by a clinical laboratory. The tests are now used for clinical diagnosis and the monitoring of therapies and patient responses. Immunology is a relatively young science and there is still so much to discover. Immunologists work in many different disease areas today that include allergy, autoimmunity, immunodeficiency, transplantation, and cancer.

Related:Immunology Conferences|Immunologists Meetings|ConferenceSeries Ltd

2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 5thEuropean Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd internationalconference on innate immunity, July 21-22, 2016, Germany; InternationalConference on Autoimmunity, October 13-14, 2016 Manchester, UK;Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Original post:
Immunology Conference | Immunology Meeting 2017 | Malaysia | Asia

How Decline in Remicade Is Affecting Merck’s Immunology Revenues – Market Realist

What's Driving Merck's Valuation in 2017? PART 6 OF 9

Remicade, one of the top-selling drugs for the treatment of inflammatory disorders, is losing its market share after the loss of exclusivity in European markets in 2015. Merck (MRK) has reported a constant decline in Remicade revenues. Apart from Merck, Johnson and Johnson (JNJ) also has marketing rights of Remicadein certain countries outside Europe.

Remicade revenues fell ~29% to $1.3 billion in 2016 as compared to $1.8 billion for 2015. The fall was mainly due to the entry of generic competitors and biosimilars following the loss of exclusivity in European markets. Merck expects Remicade revenues to fall further in the future as new patients prefer biosimilars over Remicade.

Simponi is another drug in the immunology franchise. Simponi revenues rose 11% to $766 million in 2016 as compared to $690 million for 2015.

Zetia and Vytorin are blockbuster drugs from Mercks cardiovascular portfolio. Both of these drugs are used to lower the LDL cholesterol levels in the blood. The combined revenues for these drugs fell to $3.70 billion in 2016. Global sales were affected due to the loss of exclusivity of Vytorin in the US, while Zetia sales improved 1% for 2016 as compared to 2015.

The competitors for Zetia include Niaspan from AbbVie (ABBV) and Lipitor from Pfizer (PFE). To divest the risk, investors can consider ETFs like the Health Care Select Sector SPDR ETF (XLV), which holds 6.3% of its total assets in Merck.

Original post:
How Decline in Remicade Is Affecting Merck's Immunology Revenues - Market Realist

Trinitys New Immunology Research Centre Seeks Funding from SFI – The University Times

Sinad Baker for The University Times

Trinitys newest research centre will find out in early May whether they will receive funding from Science Foundation Ireland (SFI), after a round of interviews and applications that will determine the future of the ambitious immunology institution.

Trinity is currently seeking funding from the Science Foundation Ireland (SFI), to establish the INNATE Inflammation and Immunology Research Centre in the Trinity Biomedical Sciences Institute (TBSI).

In an email to The University Times, Prof Andrew Bowie, the Head of Immunology in Trinity, confirmed that the centre has a final interview on March 1st, and should receive SFIs final decision in early May.

Bowie declined to comment further, due to the sensitive information involved in the application, which is still being considered by SFI.

SFI funding would not only see the creation of the centre but also the refurbishment of a space in TBSI in which it will be housed.

The new centre will follow a similar model to that of other Trinity research institutes, collaborating with industry and integrating researchers from other Irish universities, including University College Dublin (UCD) and Maynooth University. The centre will specialise in research on the immune system and inflammation, a bodily reaction at the centre of many diseases, including arthritis, diabetes, cancer and bowel disease.

One of the key members of the new centre is expert in immunology Prof Luke ONeill. ONeill was recently granted a lab by GlaxoSmithKline (GSK) in Stevenage, England where he will act as Trinity supervisor to two Trinity PhD students, whom GSK will fund to work with their scientists, researching immunology and inflammatory diseases. Elected as a Fellow in 2016 to the prestigious Royal Society, ONeill is one of Trinitys most successful researchers, and has attracted millions in researching funding over the years.

At a meeting of Trinitys Finance Committee in December, the committee noted that the INNATE proposal has the potential to generate a number of financial and strategic benefits for Trinity. The establishment of the centre will also include refurbishment costs for a space in TBSI, with the committee noting that the costs for the space should come from Trinitys funding contribution to the centre. Rental costs for any additional space will be met, however, by INNATE.

The committee also noted that the Faculty of Health Sciences should make a contribution to the refurbishment of the space. If the bid for funding from SFI is successful, the finance committee requested that INNATE would re-engage with the Faculty of Health Science in order to try and secure additional financial support. However if the application is unsuccessful it was was agreed that no refurbishment of TBSI would take place.

SFI currently provides funds for three research centres in Trinity: the Centre for Future Networks and Communications research (CONNECT), the Centre for Advanced Materials and Bio-Engineering Research (AMBER) and ADAPT, which specialises in digital technology. In February, Trinity received 2 million in funding from SFI for the development of the Colleges infrastructure, and numerous principal investigators and Trinity staff rely on funding from the organisation to complete their research. In 2015/16, 46 per cent of total research funding in Trinity came from SFI.

Read this article:
Trinitys New Immunology Research Centre Seeks Funding from SFI - The University Times